Terms: = Lung cancer AND MUC16, CA125, CA-125 AND Treatment
143 results:
1. Clinical effect of anlotinib in combination with docetaxel in treating advanced non-small cell lung cancer.
Weng G; Fang W; Lin Y; Chen L; Su W
Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):212-216. PubMed ID: 38678603
[TBL] [Abstract] [Full Text] [Related]
2. Determination of Tumor Marker Screening for lung cancer Using ROC Curves.
Dou X; Lu J; Yu Y; Yi Y; Zhou L
Dis Markers; 2024; 2024():4782618. PubMed ID: 38549716
[TBL] [Abstract] [Full Text] [Related]
3. Relevance of tumor markers for prognosis and predicting therapy response in non-small cell lung cancer patients: A CEPAC-TDM biomarker substudy.
Geiger K; Joerger M; Roessler M; Hettwer K; Ritter C; Simon K; Uhlig S; Holdenrieder S
Tumour Biol; 2024; 46(s1):S191-S206. PubMed ID: 38363625
[TBL] [Abstract] [Full Text] [Related]
4. Improvement of differential diagnosis of lung cancer by use of multiple protein tumor marker combinations.
Trulson I; Klawonn F; von Pawel J; Holdenrieder S
Tumour Biol; 2024; 46(s1):S81-S98. PubMed ID: 38277317
[TBL] [Abstract] [Full Text] [Related]
5. Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes.
Zhou F; Wang M; Wang Z; Li W; Lu X
BMC Cancer; 2024 Jan; 24(1):28. PubMed ID: 38166691
[TBL] [Abstract] [Full Text] [Related]
6. Predictive value of
Zhang Q; Tao X; Yuan P; Zhang Z; Ying J; Guo L; Li N; Wang S; Li J; Liu Y; Guo W; Zhao S; Wu N
Cancer Med; 2023 Nov; 12(22):20864-20877. PubMed ID: 37965789
[TBL] [Abstract] [Full Text] [Related]
7. Comprehensive characterization of muc16 mutations in lung adenocarcinoma for immunotherapies and prognosis: An observational study.
Liu T; Wu L; Liu J; Chen H; Zhu B; Qiao D; Zhu Y; Liu T; Chen Q; Hu A
Medicine (Baltimore); 2023 Nov; 102(44):e35481. PubMed ID: 37932988
[TBL] [Abstract] [Full Text] [Related]
8. CYFRA 21-1, CA 125 and CEA provide additional prognostic value in NSCLC patients with stable disease at first CT scan.
Muley T; Schneider MA; Meister M; Thomas M; Heußel CP; Kriegsmann M; Holdenrieder S; Wehnl B; Rolny V; Mang A; Gerber R; Herth F
Tumour Biol; 2024; 46(s1):S163-S175. PubMed ID: 37840516
[TBL] [Abstract] [Full Text] [Related]
9. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.
Chatterjee M; Huang LZX; Mykytyn AZ; Wang C; Lamers MM; Westendorp B; Wubbolts RW; van Putten JPM; Bosch BJ; Haagmans BL; Strijbis K
PLoS Pathog; 2023 Aug; 19(8):e1011571. PubMed ID: 37561789
[TBL] [Abstract] [Full Text] [Related]
10. Combined use of CYFRA 21-1 and CA 125 predicts survival of patients with metastatic NSCLC and stable disease in IMpower150.
Mang A; Zou W; Rolny V; Reck M; Cigoianu D; Schulze K; Holdenrieder S; Socinski MA; Shames DS; Wehnl B; Patil NS
Tumour Biol; 2024; 46(s1):S177-S190. PubMed ID: 37545290
[TBL] [Abstract] [Full Text] [Related]
11. Comparing modeling strategies combining changes in multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.
van Delft FA; Schuurbiers MMF; Muller M; Burgers SA; van Rossum HH; IJzerman MJ; van den Heuvel MM; Koffijberg H
Tumour Biol; 2024; 46(s1):S269-S281. PubMed ID: 37545289
[TBL] [Abstract] [Full Text] [Related]
12. Pre-analytical stability of the CEA, CYFRA 21.1, NSE, ca125 and HE4 tumor markers.
Canki E; Schuurbiers MM; Linders TC; Korse CM; van den Heuvel MM; van Herwaarden AE; van Rossum HH
Tumour Biol; 2024; 46(s1):S15-S25. PubMed ID: 37302060
[TBL] [Abstract] [Full Text] [Related]
13. Clinical role of serum tumor markers SCC, NSE, CA 125, CA 19-9, and CYFRA 21-1 in patients with lung cancer.
Sun A
Lab Med; 2023 Nov; 54(6):638-645. PubMed ID: 37052517
[TBL] [Abstract] [Full Text] [Related]
14. Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma.
Akarsu M; Ak G; Dündar E; Metintaş M
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7767-7778. PubMed ID: 37027032
[TBL] [Abstract] [Full Text] [Related]
15. Perioperative Effect of Single-Port Thoracoscopic Segmentectomy and Three-Port Thoracoscopic Segmentectomy in the treatment of Early Non-Small-Cell lung cancer.
Zhang C; Jiang D; Luo C; Yuan D; Shang G
Comput Math Methods Med; 2023; 2023():7550317. PubMed ID: 36873790
[TBL] [Abstract] [Full Text] [Related]
16. A case of malignant peritoneal mesothelioma with a Fitz-Hugh-Curtis syndrome-like imaging finding.
Iwadare T; Kimura T; Nagata Y; Suzuki H; Kunimoto H; Kitabatake H; Seki A; Ochi Y; Hara E; Umemura T
Clin J Gastroenterol; 2023 Jun; 16(3):372-376. PubMed ID: 36781827
[TBL] [Abstract] [Full Text] [Related]
17. Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis.
Tian H; Wang Y; Yang Z; Chen P; Xu J; Tian Y; Fan T; Xiao C; Bai G; Li L; Zheng B; Li C; He J
Cancer Gene Ther; 2023 Mar; 30(3):507-520. PubMed ID: 36653483
[TBL] [Abstract] [Full Text] [Related]
18. Increased levels of N6-methyladenosine in peripheral blood RNA: a perspective diagnostic biomarker and therapeutic target for non-small cell lung cancer.
Yin H; Hong H; Yin P; Lu W; Niu S; Chen X; Xia Y; Jiang P; Huang Z
Clin Chem Lab Med; 2023 Feb; 61(3):473-484. PubMed ID: 36542027
[TBL] [Abstract] [Full Text] [Related]
19. A case report of anterior mediastinal signet ring cell carcinoma.
Liu S; Zhao A; Mao M
Medicine (Baltimore); 2022 Dec; 101(48):e32202. PubMed ID: 36482538
[TBL] [Abstract] [Full Text] [Related]
20. Serum Markers ca125, CA153, and CEA along with Inflammatory Cytokines in the Early Detection of lung cancer in High-Risk Populations.
Li G; Zhang H; Zhang L; Liu H; Li S; Wang Y; Deng X
Biomed Res Int; 2022; 2022():1394042. PubMed ID: 36299704
[TBL] [Abstract] [Full Text] [Related]
[Next]
